Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. The company is also ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Pharmaceutical giant Eli Lilly has been experiencing a surge in revenue growth lately due to the massive popularity of its two GLP-1 drugs, Zepbound ... if there are any side effects related ...

Kyle Richards’s daughter, Sophia Umansky, shared alarming footage of her hair loss after rapidly losing weight with the help ...

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Healthify is banking on the rise of GLP-1 weight-loss drugs in India, integrating them with lifestyle coaching. The firm ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...